To address the problem of chemotherapy resistance in CXCR4 overexpressed colon cancer, a nanotoxin composed of the catalytic domain of the diphtheria toxin and CXCR4 ligand T22 was designed. The gene discussed is CXCR4; the disease is malignant colon neoplasm.